Sage Therapeutics (SAGE), Biogen (BIIB) Phase 3 for Zuranolone for Major Depressive Disorder Shows Statistically Significant Improvement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
Go back to Sage Therapeutics (SAGE), Biogen (BIIB) Phase 3 for Zuranolone for Major Depressive Disorder Shows Statistically Significant Improvement
June 15, 2021 12:07 PM EDT
Cowen analyst Ritu Baral raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $100.00) while maintaining an Outperform rating following trial data.
The analyst commented, "This AM Sage released topline data from their Ph3 WATERFALL study of 50mg zuranolone in... More
